Skip to the main content

Review article

https://doi.org/10.20471/LO.2020.48.02-03.14

First-line treatment of advanced ovarian cancer: an expert update

Branka Petrić-Miše ; Department of Oncology, University Hospital Split and School of Medicine Split, Croatia


Full text: english pdf 507 Kb

page 77-84

downloads: 563

cite


Abstract

Ovarian cancer is the fifth most common cause of death among malignant diseases in women in Europe. The standard treatment is cytoreductive surgery, followed by platinum-taxane based chemotherapy. In patients with advanced disease, a valid option is a neoadjuvant chemotherapy followed by interval debulking surgery. Despite the progress in primary treatment, almost 70% of the patients relapse. There is a significant need for better first-line treatment to avoid or delay relapse and improve ovarian cancer outcomes. The most significant change involves the changes in the treatment schedule and new drugs in first-line chemotherapy. Bevacizumab is approved in first-line treatment combined with carboplatin and paclitaxel as it improves progression-free survival (PFS) in patients with a higher risk of recurrence. After achieving the response to first-line chemotherapy, maintenance therapy with poly-adenosine-diphosphate-ribose-polymerase (PARP) inhibitors prolongs PFS in patients with homologous recombination deficiency (HRD). Patients with BRCA mutations obtain the most significant benefit.

Keywords

ovarian cancer; chemotherapy; Bevacizumab; PARP inhibitors

Hrčak ID:

250349

URI

https://hrcak.srce.hr/250349

Publication date:

21.12.2020.

Article data in other languages: croatian

Visits: 2.004 *